Renal Insufficiency, ChronicMRC-GardNCT02938611
Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France
An observational study of Renal Insufficiency, Chronic, run by Centre Hospitalier Universitaire de Nīmes at 4 sites in France.
Trial summary
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Renal Insufficiency, Chronic
- How many people
- 3,375 participants
- Where
- 4 sitesFrance
- Study dates
- 1 Jan 2019to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Persons with >= stage 4 chronic kidney disease and residing in the Gard department of France.
Who may be able to join
- chronic kidney disease (stage >= 4)
Who cannot join
- -
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France4 sites, 4 recruiting
- Recruiting
AIDER - Unité de Dialyse d'Alès
Alès, 30100
Anne Wuillai, MD
Médérick Mohajer, MD
- Not yet recruiting
AIDER - Unité de Dialyse de Nîmes, CHU Carémeau
Nîmes, 30029
Laure Patrier, MD
Emilie Pambrun, MD
- Not yet recruiting
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029
Olivier Moranne, MD, PhD
Pascal Reboul, MD
- Not yet recruiting
Gardialyse
Nîmes, 30900
Samir Boubenider, MD
Philippe Rousseau, MD
About this study
Official title: Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.
- Conditions
- Renal Insufficiency, Chronic
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| The study population | Persons with stage >=4 chronic kidney disease. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
Measured: from baseline (day 0) to 12 months
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
Measured: from baseline (day 0) to 12 months
Secondary outcomes (3)
The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
Measured: from baseline (day 0) to 12 months
For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
Measured: from baseline (day 0) to 12 months
The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
Measured: from baseline (day 0) to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2016 (estimated)
- Study start1 Jan 2019
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Insufficiency, ChronicStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 3,375 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Olivier Moranne, MD, PhD, Study director, Centre Hospitalier Universitaire de Nīmes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02938611
- Sponsor's protocol ID
- NIMAO/2016-06/OM-01
- Acronym
- MRC-Gard
- Status last verified
- Oct 2026
- First submitted
- 18 Oct 2016
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France
- ClinicalTrials.gov ID
- NCT02938611
- Acronym / sponsor ID
- MRC-Gard / NIMAO/2016-06/OM-01
- Conditions
- Renal Insufficiency, Chronic
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,375 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 19 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The study population | – | –Persons with stage >=4 chronic kidney disease. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Persons with >= stage 4 chronic kidney disease and residing in the Gard department of France.
Key inclusion criteria (1 listed)
- chronic kidney disease (stage >= 4)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
Time frame: from baseline (day 0) to 12 months
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
Time frame: from baseline (day 0) to 12 months
3 secondary outcomes
The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
Time frame: from baseline (day 0) to 12 months
For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
Time frame: from baseline (day 0) to 12 months
The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
Time frame: from baseline (day 0) to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Renal Insufficiency, Chronic
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Olivier Moranne, MD, PhD study director
Centre Hospitalier Universitaire de Nīmes
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Insufficiency, Chronic, run by Centre Hospitalier Universitaire de Nīmes at 4 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivier Moranne, MD, PhD (+33.(0)4.66.68.31.49, olivier.moranne@chu-nimes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number) (time frame: from baseline (day 0) to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.